Related by context. All words. (Click for frequent words.) 60 comparative 57 Comparison 51 Comparative Analysis 49 Pastoral Psychological 49 Multivariate 48 Supplementary Data 48 2nd edn 48 Segmental 48 Certain comparative 48 Adrian Guelke professor 48 Third Quarter Nine Months 48 Theological Responses 47 Comparability 47 Statistical Tables 47 Comparable 47 Comparative Study 47 Supplemental Table 47 Microeconomic 47 Regression Analysis 46 Comparative Figures 46 Computations 46 Practical Applications 46 Morphological 46 Meta analyzes 46 Content Outline 46 Logistic Regression 46 non GAAP Measures 46 Cost Effectiveness 46 -Keops 46 Neuroanatomy 46 Analytical Tool 46 Descriptive 46 Managements Discussion 46 Normative 46 Non Gaap 46 Univariate 45 -FALL CAMP 45 Quantification 45 Pharmacoeconomic 45 Mechanistic 45 Sensitivity Analysis 45 Segmented 45 -Kahaani Ghar Ghar Ki 45 Fourth Quarter Ended 45 Three Months EndedDecember 45 Historical Pro Forma 45 MANAGEMENT DISCUSSION AND ANALYSIS 45 Qtr Ended 45 Supplementary Appendix 45 Microstructure 45 Randomized Trials 45 Apnea Monitors 45 Summary Table 45 Microeconomics 44 Educational Attainment 44 Anthropometric 44 Thermodynamic 44 Compositional 44 OF OPERATIONS THREE MONTHS 44 Probabilistic 44 Provides Detailed 44 Constant Currency 44 YTD YTD 44 Debt Ratios 44 Clinical Outcome 44 #Q# #Q# Change [001] 44 ANCOVA 44 -Kaloki 44 MERIT ES 44 Statistical Methods 44 Predictive Toxicology 44 Percentage Change 44 -Restart 44 IFRS IFRS 44 Cash Flow Statements 44 -Tomine 44 Selected Quarterly 44 Aspergillus nidulans 44 Intravenous Equipment 44 Tweet Sentiments web 44 -Tyrell Fenroy 44 '#s except 44 Cash Flow Statement 44 Systematic Review 44 Main Outcome Measures 44 RevPAR ADR 44 Calculation 43 Alloying 43 Currency Translation 43 RESULTS OF OPERATIONS 43 Pharmacodynamic 43 Change - [002] 43 Comparative Politics 43 Clinical Implications 43 Change - [003] 43 Condensed Cash Flow 43 Seasonal Pattern 43 Geometrical 43 -Lighting Designers 43 Clinical Evaluation 43 Pro Forma Results 43 REAL ESTATE BUSINESS 43 Pro Forma Adjusted 43 Studying 43 Postdoctoral Position 43 Third Quarter Ended Nine 43 Markov Chain 43 Tabular 43 Topics Covered Executive 43 Systematic Biology 43 Hematological Cancers 43 Selected Operating 43 Reevaluation 43 Therapeutic Monoclonal Antibodies 43 mean ± SEM 43 Monographs 43 RT qPCR 43 -Hua Tian 43 Multivariate Analysis 43 corresponding reconciliations 43 LIST OF FIGURES 43 Microstructural 43 multiple logistic regression 43 Consolidated Condensed Statement 43 Phenotypic 43 LIST OF TABLES Table 43 -Soft soled shoes 43 Condensed Consolidated Interim 43 Competitive Positioning 43 Three Months Twelve Months 43 Unaudited Unaudited Unaudited Audited 43 GAAP Adj 43 Critical Perspectives 43 Clinical Practice Guideline 43 Histologic 43 WESTWOOD ONE INC. SUPPLEMENTAL 43 FOREXYARD Daily Forex 43 B.1 43 Expandable Polystyrene 43 Non GAAP Measure 43 Unaudited 43 Speciation 43 Histological 43 Summarized 43 GBPm GBPm GBPm 43 Transcriptome 43 Data Extraction 43 unaudited unaudited 43 NPS PHARMACEUTICALS INC. AND 43 SUBSIDIARIES 43 pp. #-# [006] 42 Unaudited Third Quarter 42 J Virol 42 SUBSIDIARIES Consolidated Statement 42 -Lake Andrusia 42 INC. UNAUDITED CONDENSED CONSOLIDATED 42 General Accepted Accounting 42 Three Months Nine Months 42 USGAAP 42 Epithelial Cell 42 Period Ended 42 Dietary Assessment 42 Three Months Ended Nine 42 Explanatory notes 42 Analyte 42 Randomized Controlled Trials 42 Analysis 42 -sodium chloride 42 Supplementary Table 42 GAAP Fully Diluted 42 -Raghavendra Rathore 42 THREE MONTHS ENDED DECEMBER 42 INC. Supplemental 42 - -SIRTI 42 Epidemiologic 42 #:#-# [006] 42 Histopathologic 42 Quantifiable 42 #:#-# [029] 42 Statistical Supplement Operating 42 unaudited Consolidated Statements 42 Nonclinical 42 CONSOLIDATED STATEMENT OF INCOME 42 Susceptibility Testing 42 - Aarkstore Enterprise [002] 42 Summary Balance Sheet 42 GAAP NON GAAP 42 logistic regression analyzes 42 Heterogeneity 42 Multicenter Phase 42 Histopathological 42 #Q# #Q# Var 42 SUBSIDIARIES Consolidated Statements 42 Functional Outcomes 42 Ethical Considerations 42 AND PRO FORMA 42 4th Qtr 3rd Qtr 42 Quantitative 42 Controlled Trial 42 covariance ANCOVA 42 Nine Months Nine Months 42 Postmenopausal Hormone Therapy 42 Randomized Phase II 42 Echocardiographic 42 Nucleic Acid Amplification 42 UNAUDITED Three Months 42 Unaudited Reconciliation 42 Neural Networks 42 EndedDecember 42 Temperature Maps 42 IMS MIDAS 42 Clinical Significance 42 Multiscale Modeling 42 http:/www.jdpower.com/corporate 42 Toxicological 42 SOUTHWEST BANCORP INC. 42 -gangplanks 42 Rosiglitazone Evaluated 42 Clinical Decision Making 42 TO NON GAAP MEASURES 42 Unaudited Consolidated 42 Ownership Pattern 42 Unaudited Condensed Consolidated 42 Unaudited -immanent 42 tables summarize 42 Observational Studies 42 Genotypic 42 Susceptibility 42 Appendix 42 * Reclassified 42 -Quarriers 42 Literary Criticism 42 Balance Sheet Cash Flow 42 Hepatocellular Carcinoma 42 UNAUDITED 42 Attitudes Towards 42 AND SUBSIDIARIES Segment 42 Overviews 42 Evolutionary Studies 42 -SEAMUS BRENNAN 42 NICE SUGAR 42 Psychological Assessment 42 AND SUBSIDIARIES Condensed Consolidated 42 multiple linear regression 42 Recent Accounting Pronouncements 42 Pharmacokinetic PK 42 PERCENT CHANGE 42 Pro forma 42 Cancer Incidence 42 accompanying condensed consolidated 42 Six Months Months 42 Equivalents 42 Unaudited Dollars 42 GBPm GBPm 42 Statistical Analysis 41 Consolidated Cash Flows 41 FINANCIAL SUMMARY 41 unaudited Three Months 41 -Name Directory DND 41 Pharmacokinetic 41 III #Table 41 SF #v# 41 Socioeconomic Status 41 Change - [011] 41 Animal Feed Additives 41 HUMAN SCIENCES INC. Condensed 41 Bioavailability 41 multivariable Cox 41 unaudited Amounts 41 Microbial Genome 41 Three Months Ending 41 #:#-# [037] 41 Stratification 41 Pathologic 41 microarray gene expression 41 Segment Operating 41 FINANCIAL INFORMATION 41 FIFO gross 41 Generally Accepted 41 Selectivity 41 Supplemental Non GAAP 41 Methodological 41 Empirical Evidence 41 INC. SELECTED FINANCIAL DATA 41 Measurement Uncertainty 41 Q# Q# Q# 41 unaudited Quarter Ended 41 Months Months 41 GBPm 41 PRO FORMA RESULTS 41 Molecular Epidemiology 41 Efficiency CAFE 41 Benchmarking Analysis 41 Temperature Monitoring Devices 41 OF FINANCIAL CONDITION 41 NSABP B 41 Contents Introduction 41 Various Types 41 Characterization 41 Three Months Ended Twelve 41 Psychiatric Diagnosis 41 Interventional Cardiology Devices 41 SUMMARY DATA SHEET 41 Mathematical Statistics 41 Fourth Quarter Twelve Months 41 Imaging Techniques 41 Immunogenicity 41 Oral Anticoagulants 41 Analytical Method 41 AND OTHER COMPREHENSIVE INCOME 41 PIONEER DRILLING COMPANY 41 -Edna Hibel 41 Efficacy 41 Orders Backlog 41 Cash Flow Margin 41 RECORD1 41 Modulates 41 -T#/T# 41 Overview #.#.# [002] 41 - Unaudited [015] 41 Non IFRS 41 = [026] 41 S. pombe 41 Placebo Controlled Trial 41 Phytochemistry 41 Three Months Six Months 41 Percent Percent 41 Reconciliation Tables 41 OMICS 41 Computational 41 Asset Utilization 41 Condensed consolidated 41 CITIZENS FINANCIAL SERVICES INC. 41 adjusted unlevered free 41 Dtsch Arztebl Int 41 Second Quarter Six Months 41 SEGMENT INFORMATION 41 #:#-# [027] 41 unaudited - 41 STATEMENT OF OPERATIONS 41 Cancer Epidemiol Biomarkers Prev 41 Competitive Landscape 41 COMPARATIVE FIGURES Certain 41 EBITDA Calculation 41 Inception Date 41 Microarray 41 condensed consolidated 41 AND SUBSIDIARIES 41 Critical Thinking Skills 41 multivariate statistical 41 Inflammatory Pain 41 ITS SUBSIDIARIES CONDENSED CONSOLIDATED 41 Cervical Spine 41 See Attachment 41 Quarters Ended Nine Months 41 Unconsolidated GAAP 41 Homeostasis 41 Quantitative Methods 41 Quarters Ended Six Months 41 Pathophysiology 41 Cancer Incidence Mortality 41 No. #R Consolidation 41 Forced Migration 41 2nd Qtr 1st Qtr 41 Per Share Quarter Ended 41 Geochimica et Cosmochimica Acta 41 PER SHARE AMOUNTS 41 Demography 41 Gendered 41 Bioequivalence 41 Prolongs Life 41 Corresponding 41 Taxonomy 41 Audited Unaudited 41 Bioelectromagnetics 41 Benchmarking 41 retrospectively analyzed 41 SUMMARY RESULTS 41 Gene Expression 41 pp #-# 41 Dose Response 41 Determinants 41 Prognostic Factors 41 Retained Earnings Unaudited 41 Ecological Synthesis 41 IAS IFRS 41 Adverse Event 41 Applicability 41 RMB RMB 41 journal Behavioural Ecology 41 Applied Behavior 41 Managed Balance Sheet 41 Adjust Non GAAP 41 # -GT2 RS 41 Attack Trial ALLHAT 41 Cognitive Functioning 41 Analytical Biochemistry 41 Wheat Starch 41 Clinical Pharmacokinetics 41 Algebra Geometry 41 Satellite Transponders 41 Structure Function 41 Econometrics 41 PRO FORMA 41 Graphs 41 Q#/# Q#/# [001] 41 HIGHLIGHTS UNAUDITED 41 #:#-# [016] 41 Segmental analysis 41 - Revenues [006] 41 GAAP Measures 41 RAD SVT 41 Quarterly 41 Ended Twelve Months Ended 41 Lecturer Senior Lecturer 41 Sociocultural 41 Epidemiological Survey 41 FTE headcount Three Months 41 Methods 41 CONSORT 41 UNAUDITED Amounts 41 Population Genetics 41 Synthesizing 41 Bone Metastases 41 - -Hector Allende 41 Thomson Reuters MarketScan 41 Unaudited Fourth Quarter 41 Econometric 41 QUARTER TO DATE 41 Evaluative 41 Highlights Unaudited 41 Psychiatric Epidemiology 40 Condensed Income 40 Scenario Analysis 40 * Denotes [002] 40 EXECUTIVE SUMMARY 40 Performance Indicators 40 Protein Structures 40 meta analytic 40 Dry Powder Inhalers 40 Uterine Cancer 40 Estimation 40 Comparator 40 Industrial Enzymes 40 Foreign Currency Translation 40 Carotid Endarterectomy 40 Arch Neurol 40 -#.# pp [002] 40 CALIFORNIA COASTAL COMMUNITIES INC. 40 Protein Biomarker 40 Protein Synthesis 40 Quality Indicators 40 -Amneal Pharmaceuticals LLC 40 REIT Taxable 40 covariance 40 Study Analyzes 40 Haplotype 40 unaudited Nine Months 40 Currency Majors Technical 40 Mantel Haenszel 40 GROUP RESULTS 40 UNITED MICROELECTRONICS CORPORATION 40 # -DiBacco 40 EuroIntervention 40 #:#-# [031] 40 Year Ended Ended 40 Decision Processes 40 Variance Analysis 40 Unaudited Thirteen 40 System FARS 40 Financial Ratios 40 Thymosin Beta 4 40 Critical Accounting 40 GLOSSARY OF TERMS 40 Prospective Randomized Trial 40 Homogeneity 40 SMITHFIELD FOODS INC. AND 40 DNA Microarrays 40 FUND Consolidated Statements 40 rev. ed 40 OF EARNINGS Unaudited 40 Cronbach alpha 40 Unaudited CANADIAN 40 #Table [003] 40 #:#-# [018] 40 SELECTED INCOME STATEMENT DATA 40 p.# [001] 40 NCES #-# 40 Non GAAP Disclosures 40 Incr 40 Pharmacokinetic parameters 40 Decoding 40 AND COMPREHENSIVE INCOME Unaudited 40 Unaudited Quarter Ended 40 Molecular Mechanisms 40 GAAP FINANCIAL MEASURES 40 NON GAAP RECONCILIATION 40 - -Lofoten Islands 40 Highest Quarterly 40 Meta Analysis 40 INCOME STATEMENT 40 Table 40 Virulence 40 Significant Accounting Policies 40 Year Ended 40 Teratology 40 multicenter multinational 40 Combinatorics 40 Doctoral Fellow 40 viagra WHY FANTASIES 40 bivariate 40 Standardized Distributable Cash 40 Unaudited Pro Forma 40 Visualization Equipment 40 Randomized trials 40 Anesthesia Disposables 40 Breast Carcinoma 40 Valuation Model 40 # -b Reflects 40 Mutagenesis 40 Nine Months 40 doi #.# 40 Anatomical Models 40 FINANCIAL MEASURES 40 variance ANOVA 40 allele frequencies 40 Wood Preservative Chemicals 40 Pharmacokinetics 40 Numerical Methods 40 Quarter Ended Nine Months 40 GAAP TO ADJUSTED 40 pharmacodynamic parameters 40 3rd edn 40 Yr Yr 40 AMOUNTS IN THOUSANDS EXCEPT 40 INCOME UNAUDITED 40 Cancer Res 40 Imprecise 40 Prognostic Value 40 Definitions 40 ABCSG 40 Urgent Intervention Triage 40 STATEMENTS OF EARNINGS 40 STATEMENTS OF FINANCIAL POSITION 40 - -Rough Sleepers 40 Ethnicity Race 40 DISCOVERY HOLDING COMPANY 40 unaudited Consolidated Statement 40 Observational 40 tabular amounts 40 Gastric Cancer 40 Six Months Six Months 40 Quarter Ended Quarter Ended 40 Quarters Ended Years 40 Restruc 40 Genome Sequencing 40 PharmaVitae 40 Comparing 40 Diagnostic Criteria 40 Key Ratios 40 Regulatory Frameworks 40 Supplemental Segment 40 Mathematical Methods 40 Fab Wafer 40 TO FUNDS FROM 40 Feed Acidifiers 40 Fourth Qtr 40 Biostatistics 40 #:#-# [023] 40 Survey MEPS 40 Developmental Genetics 40 Equivalent 40 Sleep Apnea Diagnostic 40 -Edgewater Networks 40 Sexual Satisfaction 40 Macroscopic 40 -dwayne tingley 40 = Per [007] 40 Solunar 40 -ABGL 40 Income Statement 40 #:#-# [022] 40 Segment Highlights 40 Segmented Results 40 Disaggregated 40 OF EARNINGS UNAUDITED 40 -hip shakin 40 Empirical 40 Acrylic Resins 40 Chess Openings 40 Comparison Tool 40 NPV IRR 40 Segment 40 Supplemental Schedule 40 Prevalence Worldwide 40 Operations unaudited 40 Taxable equivalent 40 -0 Key 40 STATEMENTS OF EARNINGS Unaudited 40 Unaudited Amounts 40 #S rRNA 40 J Pediatr 40 FINANCIAL RESULTS 40 Bacteriological 40 AND FUNDS FROM 40 Markets Analyse 40 SUBSIDIARIES Supplemental 40 Molecular Modeling 40 Tabular amounts 40 #,# NOVA MEASURING 40 Reclassified 40 DOI #.# 40 Team 4X EagleEye 40 -0 Content Outline 40 Gender Differences 40 Lies Damned Lies 40 Pharmacoeconomics 40 -Elmers 40 Beds Powered 40 EDWARDS LIFESCIENCES CORPORATION 40 Correlates 40 -Andrea Seabrook 40 Companion Diagnostics 40 Combinatorial 40 Kaplan Meier method 40 Spending Patterns 40 Hedonic 40 Quarter Ended 40 Comparative Perspectives 40 unaudited unaudited unaudited 40 CONSOLIDATED RESULTS 40 MINDRAY MEDICAL INTERNATIONAL LIMITED 40 EARNINGS SUMMARY 40 Fibre Consumption 40 Q#/FY# 40 STATEMENTS OF OPERATIONS UNAUDITED 40 NON GAAP FINANCIAL INFORMATION 40 Highlights Three Months 40 NINE MONTHS ENDED SEPTEMBER 40 Psychodynamic 40 Novel Therapeutic 40 Not Meaningful 40 Operational Metrics 40 EOG RESOURCES INC. 40 IMPACT DCM 40 J Clin Oncol 40 -Peter Van Keuren 40 TRICO MARINE SERVICES INC. 40 -Przybyl 40 Adjusted 40 - ASSETS [014] 40 Practical Aspects 40 iTRAQ 40 Och Ziff Funds 40 Lexical 40 Test Methodology 40 univariate 40 Adjusted EBITDAX 40 Bioanalytical Chemistry 40 CONDENSED CONSOLIDATED INCOME STATEMENTS 40 Molecular Genetic 40 J Immunol 40 Seasonally Adjusted 40 #S rRNA gene 40 #:#-# [019] 40 YEAR TO DATE 40 #Figure [003] 40 Protein Expression 40 Transparent Conductive 40 Microplate Readers 40 PartnerRe Ltd. Supplementary 40 Sheets Unaudited 40 Adjusted Non GAAP 40 Randomised 40 Unaudited Unaudited Audited 40 ODYSSEY HEALTHCARE INC. AND 40 Quantity kg 40 Infectious Disease Testing 40 COMPANY CONSOLIDATED INCOME STATEMENTS 40 Vitro Activity 40 Adjusted EBIT 40 Modifiable 40 Mammalian Cells 40 retrospectively adjusted 39 OPERATING RESULTS 39 # -loudly protested 39 - Adjusted [018] 39 reclassed 39 Youssef Munim head 39 Pawn Lending 39 demonstrated clinically meaningful 39 Penguin Dictionary 39 OTHER OPERATIONS 39 OF OPERATIONS AND COMPREHENSIVE 39 Acceptability 39 NHANES #-# 39 -Coco Reef 39 OPERATING HIGHLIGHTS 39 Chelating Agents 39 Computational Genomics 39 - UnaudCrouppen 39 - Babelgum Online 39 Biochemical Sciences 39 Double Blind Randomized 39 READER ADVISORY 39 Factors Impacting 39 Socio demographic 39 #.#.# [037] 39 Moral Foundations 39 Oilfield Chemicals 39 Long Lesion 39 SIGNIFICANT ACCOUNTING POLICIES 39 YEAR ENDED DECEMBER 39 Adjustment Non GAAP 39 OPERATING AND 39 FINANCIAL CONDITION AND 39 Therapeutic Efficacy 39 Factors Influencing 39 Condensed Consolidated 39 Operations Unaudited 39 2nd Qtr '# 39 Predecessor Successor 39 Ended - [011] 39 Three Months Ended 39 CALGB 39 Brain Function 39 -AL Gustin 39 Bioinformatic 39 MONTHS ENDED 39 OPERATIONS UNAUDITED 39 Phylogeny 39 Longitudinal Studies 39 -prosumer 39 GAAP ments 39 REPORTED RESULTS 39 Pro Forma Non GAAP 39 Supplemental Figure 39 BROOKLINE BANCORP INC. AND 39 Invasive Fungal Infections 39 Homogeneous 39 STEALTH C 39 QUARTERS ENDED 39 FINANCIAL STATEMENTS 39 Psychiatry #:#-# [002] 39 Monte Carlo Simulation 39 Radiation Induced 39 Mathematics Teaching 39 Months Ended -Oracle #g databases 39 Pharmacogenetics 39 Twelve Months Ending 39 Three Months Months Ended 39 Correlated 39 Adjusted Diluted EPS 39 Six Months Ended 39 #:#-#,# CrossRef Medline [002] 39 Adversely Affects 39 Aruvian Research 39 Antiangiogenic 39 Conformational 39 Mouse Genome 39 Q3 YTD 39 Intervention Trial 39 Overview 39 CT Angiography 39 STATISTICS Unaudited 39 Board APB Opinion 39 HERTZ GLOBAL HOLDINGS INC. 39 Quarter Ended #/#/# #/#/# [002] 39 Biobehavioral 39 Ultrasound Equipment 39 POLYCOM INC. GAAP 39 Racial Attitudes 39 Multicenter 39 Reported Adjustments Non GAAP 39 Gendering 39 Hematological 39 C.1 39 #:#-#,# [002] 39 Angiographic 39 Quantitative RT PCR 39 TWELVE MONTHS ENDED DECEMBER 39 Selected Balance Sheet 39 CONSOLIDATED BALANCE SHEET UNAUDITED 39 Descriptive statistics 39 DCT INDUSTRIAL TRUST INC. 39 Releases Audited 39 Endometrial Cancer 39 ODOT Fatality Analysis 39 Contained Metal 39 Supplementary Information 39 OPERATIONS Amounts 39 Isotopic 39 Socio Political 39 BizAcumen LLC 39 CONSOLIDATED STATEMENT OF 39 AND SUBSIDIARIES Consolidated Statements 39 Ultrasensitive 39 Biosynthesis 39 NORTHERN TRUST CORPORATION Supplemental 39 AND COMPREHENSIVE INCOME 39 Psychobiology 39 Pro Forma Net 39 correlation coefficients 39 Introduction 39 Serology 39 GAAP FINANCIAL INFORMATION 39 Three Month Periods 39 Sensorimotor 39 ASC Topic #-# 39 Signaling Pathways 39 retroactively restated 39 Multicenter Study 39 Seriously Flawed 39 HIGHLIGHTS Three Months 39 clinico pathological 39 3rd Qtr 4th Qtr 39 BALANCE SHEETS Unaudited 39 EOG RESOURCES INC. SUMMARY 39 Multivariable 39 unaudited unaudited -watchdog BaFin 39 Tumor Response 39 Regulatory Developments 39 Randomized Clinical Trials 39 SELECTED FINANCIAL AND 39 Regulatory Toxicology 39 immunohistochemical 39 Grocery Retailing 39 ROLLINS INC. AND SUBSIDIARIES 39 Normalized 39 Metallic Materials 39 1st Qtr 2nd Qtr 39 Variability 39 STATEMENTS OF OPERATIONS 39 Meta Analyses 39 Unfav 39 Coronary CTA 39 Statistical Summary 39 SUBSIDIARIES Condensed Consolidated Statements 39 GULF RESOURCES INC. AND 39 Behavioral Neurobiology 39 COMMERCE BANCSHARES INC. 39 Predisposition 39 Pt Chg 39 Developmental Therapeutics 39 Darbepoetin Alfa 39 =America Airline Satisfaction 39 Recent Past 39 Geography Geology 39 Toxicity Testing 39 National Inpatient Sample 39 DATA unaudited 39 SUBSIDIARIES Consolidated Balance Sheets 39 = [028] 39 - unaudited [008] 39 journal Molecular Pharmaceutics 39 gene annotation 39 conducted retrospective cohort 39 -tiger muskies 39 Myocardial Perfusion 39 Match Fixtures 39 = [044] 39 Condensed Historical 39 CrossRef Medline 39 Quarter Quarter Ended 39 retrospectively restated 39 Inherited Disease 39 Pinpoint Demographics 39 GLOBOCAN 39 FINANCIAL OVERVIEW 39 UNAUDITED CONSOLIDATED BALANCE SHEETS 39 Qtr Qtr Qtr Qtr 39 Sentinel Lymph Node Biopsy 39 Gene Silencing 39 Racial Differences 39 RMB RMB USD 39 Biobanks 39 STATEMENTS OF CONSOLIDATED INCOME 39 methodologic 39 Pooled Analysis 39 Antitumor 39 Sequential Quarter 39 FINANCIAL INFORMATION UNAUDITED 39 Toxicogenomics 39 SUBSIDIARIES BUSINESS SEGMENT 39 Electrophysiological 39 Highly Selective 39 Fourth Quarter Ended Twelve 39 Pharmacogenomic 39 Income Inequality 39 Digging Into 39 EARNINGS Taxable equivalent 39 Eds. 39 CONDENSED STATEMENT OF OPERATIONS 39 SUBSIDIARIES Condensed Consolidated 39 Sciencein 39 Assessment Questionnaire 39 Ended -Agility SAP 39 Analyzing 39 ended -David Gozal 39 clinicopathological 39 #:#-# [033] 39 Antihypertensive 39 SUMMARY OF QUARTERLY RESULTS 39 Month Period Ended 39 Tumor Cell 39 OF INCOME unaudited 39 Cognitive Abilities 39 Workplace Hazardous Materials 39 Immunohistochemical 39 NOI FFO 39 Phylogenetic 39 -firewall router 39 3rd Qtr 2nd Qtr 39 DKKm 39 Condensed Consolidated Cash Flow 39 B.3 39 -ANDREA SACHS 39 SUMMARY OF RESULTS 39 STATEMENTS OF 39 unaudited -Nesha Starcevic 39 Key Topics Covered 39 Musculoskeletal Disorders 39 APPENDIX 39 Operations Unaudited Dollars 39 biochemistry physiology 39 Income Unaudited Amounts 39 Comparable EBITDA 39 Veterinary Vaccines 39 Complementarity 39 unaudited audited 39 Determinant 39 Reevaluating 39 -6News Jennifer 39 Automotive Sensors 39 Industrial Protective Clothing 39 Hidden Markov 39 - Unaudited [013] 39 OSIs 39 CFS BANCORP INC. 39 Historical Perspective 39 Stent Placement 39 Authority QSA 39 Analytical Methods 39 Preoperative 39 Protein Interactions 39 Recalculation 39 Six Months Ended -Ronald Moten 39 Nanopatterning 39 OF SEPTEMBER 39 Genetically Engineered Animals 39 Toxicological Sciences 39 #-#/# [022] 39 #.#c #.#c [002] 39 Diagnosis Treatment 39 Prognostic 39 SUBSIDIARIES UNAUDITED CONSOLIDATED STATEMENTS 39 Molecular Biomarkers 39 FINANCIAL RESULTS RECONCILIATION OF 39 Molecular Evolution 39 Chartered Accountants Handbook 39 UNAUDITED THREE MONTHS ENDED 39 BUSINESS DESCRIPTION 39 Tjeerdema chairs 39 intersegment eliminations 39 MarketAxess Announces 39 Comparative Condensed Consolidated Statements 39 AND SUBSIDIARIES SEGMENT REPORTING 39 SELECTED RATIOS 39 Competitive Scenario 39 Mineral Resource estimation 39 #:#-# [014] 39 Dose Ranging 39 ScD MPH 39 J Rheumatol 39 Y Chromosome 39 sm Nasdaq NDAQ 39 Eukaryotic 39 Genotype 39 CONSOLIDATED SUBSIDIARIES CONDENSED CONSOLIDATED 39 Trace Element 39 SUMMARY TABLE 39 © Jihad Unspun 39 Twelve Twelve Months 39 FINANCIAL AND OPERATIONAL 39 Multivariate logistic regression 39 Factors Affecting 39 Unaudited Unaudited 39 Per Per 39 Practitioner Guide 39 Mathematical Models 39 Sherri Muzher 39 - RevGreencool 39 Glycemic 39 Managerial Accounting 39 Non GAAP Reconciliations 39 IBERIABANK CORPORATION CONDENSED CONSOLIDATED 39 Unaudited Twelve Months 39 Pro Forma 39 Prolongs Survival